Search research articles
Contact Us
Filters
Showing results (161-170 of 253) with videos related to
Page
of 26
Sort By:
JNCI Cancer Spectrum
|
July 16, 2025
Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study
Amy L Shaver, Krupa Gandhi, Scott W Keith, et al.
Clinical Genitourinary Cancer
|
September 5, 2018
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma
Michael E Hurwitz, Paul Markowski, Xiaopan Yao, et al.
Clinical Prostate Cancer
|
January 8, 2005
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse
Darko Pucar, Jason A Koutcher, Ankoor Shah, et al.
Currents in Pharmacy Teaching & Learning
|
April 28, 2020
A student initiative to implement peer-led study groups for a pharmacogenomics course: Evaluation of student performance and perceptions
Boris Zhang, Sarah Kim, Yaoyi Xiao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
Maha Hussain, Dana Rathkopf, Glenn Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy
Michael J Morris, Timothy Akhurst, Steven M Larson, et al.
Internal and Emergency Medicine
|
October 12, 2021
Comparison of characteristics and outcomes of patients admitted to hospital with COVID-19 during wave 1 and wave 2 of the current pandemic
David Fluck, Suzanne Rankin, Andrea Lewis, et al.
Cancer Immunology, Immunotherapy : CII
|
July 11, 2007
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"
Susan F Slovin, Govind Ragupathi, Celina Fernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
Matthew D Galsky, Eric J Small, William K Oh, et al.
Psychological Trauma : Theory, Research, Practice and Policy
|
May 10, 2019
An epidemiological evaluation of trauma types in a cohort of deployed service members
Candice Presseau, Brett T Litz, Nora K Kline, et al.
Page
of 26
Search research articles
Search
Showing results (161-170 of 253) with videos related to
Sort By:
Page
of 26
JNCI Cancer Spectrum
|
July 16, 2025
Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study
Amy L Shaver, Krupa Gandhi, Scott W Keith, et al.
Clinical Genitourinary Cancer
|
September 5, 2018
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma
Michael E Hurwitz, Paul Markowski, Xiaopan Yao, et al.
Clinical Prostate Cancer
|
January 8, 2005
Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse
Darko Pucar, Jason A Koutcher, Ankoor Shah, et al.
Currents in Pharmacy Teaching & Learning
|
April 28, 2020
A student initiative to implement peer-led study groups for a pharmacogenomics course: Evaluation of student performance and perceptions
Boris Zhang, Sarah Kim, Yaoyi Xiao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 18, 2015
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer
Maha Hussain, Dana Rathkopf, Glenn Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 4, 2005
Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy
Michael J Morris, Timothy Akhurst, Steven M Larson, et al.
Internal and Emergency Medicine
|
October 12, 2021
Comparison of characteristics and outcomes of patients admitted to hospital with COVID-19 during wave 1 and wave 2 of the current pandemic
David Fluck, Suzanne Rankin, Andrea Lewis, et al.
Cancer Immunology, Immunotherapy : CII
|
July 11, 2007
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?"
Susan F Slovin, Govind Ragupathi, Celina Fernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2005
Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
Matthew D Galsky, Eric J Small, William K Oh, et al.
Psychological Trauma : Theory, Research, Practice and Policy
|
May 10, 2019
An epidemiological evaluation of trauma types in a cohort of deployed service members
Candice Presseau, Brett T Litz, Nora K Kline, et al.
Page
of 26